Welcome to SynapCell
SynapCell is a preclinical Contract Research Organization which provides translational solutions to evaluate the therapeutic potential of CNS drug candidates in epilepsy. SynapCell provides customized solutions which cover the entire range of customers needs, from early steps to the final answer.
SynapCell to screen for novel treatments for pharmacoresistant epilepsies
Grenoble (France) and Salt Lake City, Utah (USA), January 29th, 2014 –
The University of Utah awards a subcontract to SynapCell to expand anti-seizure drug screening and testing capabilities in animal models of therapy-resistant epilepsy
The University of Utah has awarded a one-year subcontract to SynapCell under the Anticonvulsant Screening Program (ASP) contract sponsored by the NIH National Institute of Neurological Disorders and Stroke (NINDS). This subcontract will supplement the existing University of Utah program to test promising anti-seizure drug candidates in a mouse model of therapy-resistant mesial temporal lobe epilepsy (MTLE).